Publicaciones en colaboración con investigadores/as de University of Würzburg (14)

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

2022

  1. Genomic profiling for clinical decision making in lymphoid neoplasms

    Blood

2019

  1. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

    Leukemia, Vol. 33, Núm. 1, pp. 159-170

2017

  1. Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial

    British Journal of Haematology, Vol. 179, Núm. 1, pp. 66-74

2016

  1. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by prior treatment

    Blood, Vol. 127, Núm. 6, pp. 713-721

  2. The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective

    Advances in Therapy, Vol. 33, Núm. 11, pp. 1896-1920

2015

  1. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone

    Haematologica, Vol. 100, Núm. 10, pp. 1327-1333

  2. Global myeloma research clusters, output, and citations: A bibliometric mapping and clustering analysis

    PLoS ONE, Vol. 10, Núm. 1

2014

  1. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

    Journal of Clinical Oncology, Vol. 32, Núm. 6, pp. 587-600

2010

  1. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

    Leukemia, Vol. 24, Núm. 6, pp. 1121-1127

2009

  1. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

    Leukemia, Vol. 23, Núm. 10, pp. 1904-1912

  2. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

    Blood, Vol. 114, Núm. 9, pp. 1729-1735

2008

  1. Lenalidomide: A new therapy for multiple myeloma

    Cancer Treatment Reviews, Vol. 34, Núm. 3, pp. 283-291

2005

  1. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies

    Cancer Treatment Reviews, Vol. 31, Núm. 8, pp. 591-602